Wim M. Mulleners

2.8k total citations · 1 hit paper
47 papers, 1.8k citations indexed

About

Wim M. Mulleners is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Wim M. Mulleners has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Psychiatry and Mental health, 21 papers in Pathology and Forensic Medicine and 9 papers in Neurology. Recurrent topics in Wim M. Mulleners's work include Migraine and Headache Studies (30 papers), Trigeminal Neuralgia and Treatments (21 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Wim M. Mulleners is often cited by papers focused on Migraine and Headache Studies (30 papers), Trigeminal Neuralgia and Treatments (21 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Wim M. Mulleners collaborates with scholars based in Netherlands, United States and Norway. Wim M. Mulleners's co-authors include Edward P. Chronicle, Mattias Linde, Douglas C McCrory, Peter J. Koehler, J.W. Vredeveld, Bastiaan R. Bloem, Sebastiaan Overeem, Roel Vermeulen, Hans Kromhout and Antonetta M. G. Sas and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Wim M. Mulleners

42 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

2020 168 citations Wim M. Mulleners, Byung‐Kun Kim et al. The Lancet Neurology profile →

Peers

Countries citing papers authored by Wim M. Mulleners

Since Specialization

Citations

This map shows the geographic impact of Wim M. Mulleners's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim M. Mulleners with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim M. Mulleners more than expected).

Fields of papers citing papers by Wim M. Mulleners

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim M. Mulleners. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim M. Mulleners. The network helps show where Wim M. Mulleners may publish in the future.

Co-authorship network of co-authors of Wim M. Mulleners

This figure shows the co-authorship network connecting the top 25 collaborators of Wim M. Mulleners. A scholar is included among the top collaborators of Wim M. Mulleners based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim M. Mulleners. Wim M. Mulleners is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beyond coincidence: a case series on the clinical course of coinciding cluster headache and short-lasting unilateral neuralgiform headache attacks 2025 ·PAIN Reports ·Jeroen J. Jansen, (unknown), (unknown), Rolf Fronczek, Wim M. Mulleners	0
2	Occipital nerve stimulation for cluster headache: lessons to learn from the ‘voltage tuners’ 2024 ·The Journal of Headache and Pain ·(unknown), (unknown), (unknown), (unknown), Christopher L. Robinson, (unknown), Wim M. Mulleners, Erkan Kurt	1
3	Four Decades of Occipital Nerve Stimulation for Headache Disorders: A Systematic Review 2024 ·Current Pain and Headache Reports ·(unknown), Erkan Kurt, Wim M. Mulleners, Alaa Abd‐Elsayed, Cyrus Yazdi, Michael E Schatman, R. Jason Yong, (unknown), (unknown), Sait Ashina, Christopher L. Robinson, (unknown)	6
4	Intra- and interindividual attack frequency variability of chronic cluster headache 2023 ·Cephalalgia ·Roemer B. Brandt, Wim M. Mulleners, Leopoldine A. Wilbrink, (unknown), Erik W. van Zwet, Frank Huygen, Michel D. Ferrari, Rolf Fronczek, (unknown)	1
5	A prospective open label 2–8 year extension of the randomised controlled ICON trial on the long-term efficacy and safety of occipital nerve stimulation in medically intractable chronic cluster headache 2023 ·EBioMedicine ·Roemer B. Brandt, Leopoldine A. Wilbrink, (unknown), Joost Haan, Wim M. Mulleners, Frank Huygen, (unknown), Michel D. Ferrari, Rolf Fronczek, (unknown), (unknown), (unknown), (unknown), Erkan Kurt, R.T.M. van Dongen, Onno Teernstra, Peter J. Koehler, G.H. Spincemaille, Frank Wille, Katja Bürger, (unknown), (unknown), Jan Willem Kallewaard, Petrus H. Veltink, Rik Buschman	7
6	The Untold Story of Occipital Nerve Stimulation in Patients With Cluster Headache: Surgical Technique in Relation to Clinical Efficacy 2023 ·Neuromodulation Technology at the Neural Interface ·Erkan Kurt, (unknown), Robert van Dongen, (unknown), Wim M. Mulleners, (unknown)	5
7	A Randomized, Placebo-Controlled Study of Galcanezumab in Patients with Treatment-Resistant Migraine: Double-Blind Results from the CONQUER Study (162) 2020 ·Neurology ·Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez, Michel Lantéri‐Minet, Sheena K. Aurora, Russell Nichols, Shufang Wang, Antje Tockhorn‐Heidenreich, Holland C. Detke	10
8	Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial breakdown → 2020 ·The Lancet Neurology ·Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez, Michel Lantéri‐Minet, Patricia Pozo‐Rosich, Shufang Wang, Antje Tockhorn‐Heidenreich, Sheena K. Aurora, Russell Nichols, (unknown), Holland C. Detke	168
9	Parkinson's disease and long-term exposure to outdoor air pollution: A matched case-control study in the Netherlands 2019 ·Environment International ·R. Toro, George S. Downward, Marianne van der Mark, Maartje Brouwer, Anke Huss, Susan Peters, Gerard Hoek, Peter C.G. Nijssen, Wim M. Mulleners, Antonetta M. G. Sas, Teus van Laar, Hans Kromhout, Roel Vermeulen	47
10	Development and psychometric validation of the headache screening questionnaire – Dutch Version 2017 ·Musculoskeletal Science and Practice ·(unknown), Corine M. Visscher, Raoul Engelbert, Wim M. Mulleners, Maria W. G. Nijhuis–van der Sanden, Caroline M. Speksnijder	21
11	Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands 2017 ·Environment International ·Maartje Brouwer, Anke Huss, Marianne van der Mark, Peter C.G. Nijssen, Wim M. Mulleners, Antonetta M. G. Sas, Teus van Laar, G.R. de Snoo, Hans Kromhout, Roel Vermeulen	122
12	Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease 2015 ·Parkinsonism & Related Disorders ·Marianne van der Mark, Roel Vermeulen, Peter C.G. Nijssen, Wim M. Mulleners, Antonetta M. G. Sas, Teus van Laar, Anke Huss, Hans Kromhout	19
13	A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking 2014 ·PLoS ONE ·Marianne van der Mark, Peter C.G. Nijssen, Jelle Vlaanderen, Anke Huss, Wim M. Mulleners, Antonetta M. G. Sas, Teus van Laar, Hans Kromhout, Roel Vermeulen	73
14	Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinson’s disease 2014 ·International Archives of Occupational and Environmental Health ·Marianne van der Mark, Roel Vermeulen, Peter C.G. Nijssen, Wim M. Mulleners, Antonetta M. G. Sas, Teus van Laar, Hans Kromhout, Anke Huss	16
15	Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands 2014 ·Occupational and Environmental Medicine ·Marianne van der Mark, Roel Vermeulen, Peter C.G. Nijssen, Wim M. Mulleners, Antonetta M. G. Sas, Teus van Laar, Maartje Brouwer, Anke Huss, Hans Kromhout	28
16	Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT) 2013 ·The Lancet Neurology ·Marjolein A. van der Marck, Marten Munneke, Wim M. Mulleners, Edo M Hoogerwaard, George F. Borm, Sebastiaan Overeem, Bastiaan R. Bloem	89
17	The ParkinsonNet concept: Development, implementation and initial experience 2010 ·Movement Disorders ·Maarten J. Nijkrake, S.H.J. Keus, Sebastiaan Overeem, R.A.B. Oostendorp, T. P. M. Vliet Vlieland, Wim M. Mulleners, Edo M Hoogerwaard, Bastiaan R. Bloem, Marten Munneke	68
18	Allied health care in Parkinson's disease: Referral, consultation, and professional expertise 2008 ·Movement Disorders ·Maarten J. Nijkrake, S.H.J. Keus, R.A.B. Oostendorp, Sebastiaan Overeem, Wim M. Mulleners, Bastiaan R. Bloem, Marten Munneke	69
19	Referral to non-pharmacological interventions in Parkinson's disease. 2005 ·Parkinsonism & Related Disorders ·Maarten J. Nijkrake, Bastiaan R. Bloem, Wim M. Mulleners, R.A.B. Oostendorp, Marten Munneke	2
20	Assessing Cortical Excitability in Migraine: Reliability of Magnetic Suppression of Perceptual Accuracy Technique Over Time 2005 ·Headache The Journal of Head and Face Pain ·(unknown), Wim M. Mulleners, Edward P. Chronicle	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact